Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
Gabapentin and its salts and derivativesF1 I SEP / 98
Galantamine and its salts and derivativesF1 I OCT / 03
Gallamine triethiodideF1 I SEP / 98
Gallium and its saltsF1 I SEP / 98
Ganciclovir and its saltsF1 I SEP / 98
Ganirelix and its salts and derivativesF1 I MAY / 04
Gatifloxacin and its salts and derivativesF1 I JUL / 03
GefitinibF1 I SEP / 06
Gemcitabine and its saltsF1 I SEP / 98
Gemfibrozil and its saltsF1 I SEP / 98
Gemifloxacin and its saltsF1 I SEP / 06
Gentamicin and its salts and derivativesF1 I SEP / 98
Gentian Violet II DEC / 01
Glatiramer and its saltsF1 I SEP / 98
GliclazideF1 I SEP / 98
GlimepirideF1 I MAY / 04
GlipizideF1 I SEP / 98
Glucagon II SEP / 98
Glutamic acid and its salts gastric acidifiers U FEB / 99
GlutethimideF1 I SEP / 98
Glyburide and its salts and derivativesF1 I SEP / 98
Glyceroargentinate III SEP / 98
Glycopyronium bromidePDL

when used for inhalation

I DEC / 13
Glycopyrrolate or its salts except glycopyronium bromide when used for inhalation II DEC / 13
Gold or its salts or derivativesPDL

including but not limited to aurothioglucose, auranofin and sodium aurothiomalate, when sold for administration by injection

I DEC / 13
GolimumabF1 I MAR / 11
Gonadorelin and its saltsF1 I SEP / 98
Gonadotropin, chorionicF1 human I SEP / 98
Gonadotropin, serumF1 human I SEP / 98
Goserelin and its saltsF1 I SEP / 98
Gramicidin and its salts for topical use U
Gramicidin and its salts and derivatives for ophthalmic use III JUN / 06
Granisetron and its saltsF1 I SEP / 98
GrazoprevirPDL I AUG / 16
Grepafloxacin and its salts and derivativesF1 I SEP / 99
Griseofulvin and its salts and derivativesF2 I SEP / 98
Guaifenesin U
Guanethidine and its saltsF1 I SEP / 98

38 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled